TrialMed (New York, N.Y.)2022

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19.

Oliver J McElvaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.